Filing Details
- Accession Number:
- 0000914190-17-000236
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-08-11 17:35:42
- Reporting Period:
- 2017-08-11
- Filing Date:
- 2017-08-11
- Accepted Time:
- 2017-08-11 17:35:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1196298 | Nephros Inc | NEPH | Surgical & Medical Instruments & Apparatus (3841) | 133971809 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1411726 | Daron Evans | C/O Nephros, Inc. 41 Grand Avenue River Edge NJ 07661 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-08-11 | 70,000 | $0.26 | 683,378 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 51,666 | Indirect | By UTMA #1 |
| Common Stock | 49,166 | Indirect | By UTMA #2 |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | $0.46 | 2024-03-26 | 75,361 | 75,361 | Direct | |
| Common Stock | Stock Option (Right to Buy) | $0.60 | 2025-04-15 | 764,468 | 764,468 | Direct | |
| Common Stock | Common Stock Warrants (Right to Buy) | $0.30 | 2016-06-03 | 2021-06-03 | 40,000 | 40,000 | Indirect |
| Common Stock | Common Stock Warrants (Right to Buy) | $0.30 | 2016-06-03 | 2021-06-03 | 10,000 | 10,000 | Indirect |
| Common Stock | Common Stock Warrants (Right to Buy) | $0.30 | 2016-06-03 | 2021-06-03 | 10,000 | 10,000 | Indirect |
| Common Stock | Common Stock Warrants (Right to Buy) | $0.30 | 2017-03-17 | 2022-03-17 | 41,666 | 41,666 | Indirect |
| Common Stock | Common Stock Warrants (Right to Buy) | $0.30 | 2017-03-17 | 2022-03-17 | 41,666 | 41,666 | Indirect |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2024-03-26 | 75,361 | 75,361 | Direct |
| 2025-04-15 | 764,468 | 764,468 | Direct |
| 2021-06-03 | 40,000 | 40,000 | Indirect |
| 2021-06-03 | 10,000 | 10,000 | Indirect |
| 2021-06-03 | 10,000 | 10,000 | Indirect |
| 2022-03-17 | 41,666 | 41,666 | Indirect |
| 2022-03-17 | 41,666 | 41,666 | Indirect |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.2545 to $0.2771 inclusive. The reporting person undertakes to provide Nephros, Inc., any security holder of Nephros, Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- Includes 9,165 shares of restricted stock that vest on June 14, 2017, 213,068 shares of restricted stock that vest on June 23, 2017 and 17,756 shares of restricted stock that vest on September 30, 2017.
- Fully exercisable.
- On 4/15/2015, the Reporting Person was granted an option to purchase up to 2,184,193 shares of common stock of the Company. 35% of the shares subject to the option (relating to a total of 764,468 shares) vest quarterly in 16 equal amounts, commencing on 6/30/2015. 15% of the shares subject to the option will vest, if ever, upon the listing of the Company's common stock on NASDAQ, NYSE, or such other exchange as the Board may later determine. The remaining 50% of the shares subject to the option will vest, if ever, upon the Company's achievement of certain annual revenue milestones as specified in that certain Employment Agreement dated 4/15/2015 between the Reporting Person and the Company.
- The Reporting Person is a managing director of the LLC that owns the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Billionaire Hedge Funds
